Psychiatr. pro Praxi, 2006; 4: 158-160

Long-term treatment of schizophrenia

MUDr. Klára Látalová, doc. MUDr. Vladimír Pidrman Ph.D
Psychiatrická klinika FN a LF UP, Olomouc

Schizophrenia is a serious psychotic disease with a prolonged course, significant functional affection and reduced quality of life in its characteristics. Disease has a serious impact on patients families and whole society. The aim of long-term treatment is maintenance of improvement which was acquired during acute or stabilizing treatment, prevention of relapse, elimination of negative signs and formation conditions for return to a full social competence.

Keywords: schizophrenia, long-term treatment, antipsychotics

Published: August 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K, Pidrman V. Long-term treatment of schizophrenia. Psychiatr. praxi. 2006;7(4):158-160.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almond S, Knapp M, Francois C, Tuomi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry, 2004; 184: 346-351. Go to original source... Go to PubMed...
    2. American Psychiatric Associacion. Practice guidelines for the treatment of patients with schizophrenia. Washingotn, D.C., APA 1997.
    3. Awas AG, Hogan TP. Subjective response to neuroleptics and quality of life: implication for treatment outcome. Acta Psychiat Scand., 1994; 89, Suppl. 380: 27-32. Go to original source... Go to PubMed...
    4. Bouček J, Pidrman V. Psychofarmaka v medicíně. Grada Publishing 2004, 286 s.
    5. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiat, 2003; 64 (10): 1250-1257. Go to original source... Go to PubMed...
    6. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiat 2001;62 (suppl): 10-14.
    7. Jarolímek M. Psychoterapie (vycházející z KBT) u schizofrenních poruch. Psychiatrie, 2004; Suppl. 4: 9-10.
    8. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drug on neurocognition in first-epizode psychosis: a randomized, double - blind trial of olanzapine versus low doses of haloperidol. Am J Psych 2004; 161: 985-995. Go to original source... Go to PubMed...
    9. Keith, SJ, Kane, JM. Partial compliance and patient consequences in schizophrenia. J Clin Psychiat., 2003; 8: 1308-1315. Go to original source... Go to PubMed...
    10. Höschl C, Libiger J, Švestka J. Psychiatrie. 2. doplněné a opravené vydání. Praha, Tigis 2004.
    11. Hughes I, et al. Compliance with antipsychotic medication: From theory to practice. J Mental Health, 1999; 5: 473-489. Go to original source...
    12. Leucht S, Barnes TRE, Kissling W, Engel RR, Correl C, Kane JM. Relapse prevention in schizophrenia with ne generation antipsychotics: a systematic rewiew and exploratory meta analysis of randomized, controlled trials. Am J Psychiat, 2003; 7: 1209-22. Go to original source... Go to PubMed...
    13. Leucht S, Wahlbeck K, Haman J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic rewiew and meta-analysis. Lancet, 2001; 361: 1581-1589. Go to original source... Go to PubMed...
    14. Lieberman JA, Stroups TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. med. 2005; 353: 1209-23. Go to original source... Go to PubMed...
    15. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharamacol 2001; 11: 25-32. Go to original source... Go to PubMed...
    16. Mc Evoy, et al. TheExpert consensus Guideline Series: treatment of schizofrenia. J Clin psychiatry 1999; 60(Suppl 11): 80.
    17. Mc Glashan TH. A selective review of recent North American long-term follow up of a Dutch incidence cohort. Schizophr Bull, 1998, 24: 75-85. Go to PubMed...
    18. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiat 2001; 62 (Suppl 27): 35-39.
    19. Meyer JM. Effects of atypical antipsychotics onweight and serum lipid levels. J Clin Psychiat. 2001; 62 (Suppl 27): 27-34.
    20. Mohr, P. Terapie farmakorezistentní schizofrenie. Psychiatrie, 2003; 7, Suppl. 1: 28-30.
    21. Motlová L, Dragomirecká E, Španiel F et al. Vliv rodinné psychoedukace u schizofrenie na kvalitu života pacientů a jejich příbuzných. Psychiatrie, 2002; 6 (Suppl. 4): 46-49.
    22. Motlová L, Koukolík F. Schizofrenie neurobiologie, klinický obraz, terapie. Galén, 2004.
    23. Nadeem BH, Chouinard G, Howard MC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol, 2004; 14:87-92. Go to original source... Go to PubMed...
    24. Peuskens J. Risperidon in the treatment of the patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallel group study versus haloperidol. Br J Psychia. 1995; 166: 712-26. Go to original source... Go to PubMed...
    25. Seifertová D, Praško J, Höschl C. Postupy v léčbě psychických poruch. Praha, Academia Medica Pragensis 2004, 450.
    26. Shiloh R, Nutt D, Wezman A. Atlas of psychotropic pharmacotherapy. London, Martin Dunitz 2000.
    27. Svačina Š. Metabolické účinky psychofarmak. Triton 2004.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.